A randomized, eight-week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (300/5 mg and 300/10 mg) in comparison with aliskiren 300 mg in patients with essential hypertension not adequately responsive to aliskiren 300 mg monotherapy.
- Registry ID
- EUCTR2006-006066-42
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Novartis Pharma Services AG
- Start date
- 2008-10-01
- Completion date
- 2009-05-28
- Last update
- 2026-08-16
Conditions
- Hipertensión
- essential hypertension
- hypertension
Summary
Demonstrate the efficacy of the combination therapies of aliskiren/amlodipine (300mg/5 mg and 300/10 mg) in hypertensive patients who do not show sufficient blood pressure response to a 4-week treatment of aliskiren 300 mg by testing the hypothesis of superior reduction in mean sitting diastolic blood pressure (msDBP) from baseline to end of study when compared to aliskiren 300 mg monotherapy.
Locations
- , , France
- , , Spain
- , , Iceland
- , , Italy
- , , Lithuania
- , , Estonia
View on source registry